405 related articles for article (PubMed ID: 31124335)
1. Real-World Analysis of the Efficacy of Rebiopsy and
Hong MH; Kim HR; Ahn BC; Heo SJ; Kim JH; Cho BC
Yonsei Med J; 2019 Jun; 60(6):525-534. PubMed ID: 31124335
[TBL] [Abstract][Full Text] [Related]
2. Primary resistance to osimertinib due to SCLC transformation: Issue of T790M determination on liquid re-biopsy.
Minari R; Bordi P; Del Re M; Facchinetti F; Mazzoni F; Barbieri F; Camerini A; Comin CE; Gnetti L; Azzoni C; Nizzoli R; Bortesi B; Rofi E; Petreni P; Campanini N; Rossi G; Danesi R; Tiseo M
Lung Cancer; 2018 Jan; 115():21-27. PubMed ID: 29290257
[TBL] [Abstract][Full Text] [Related]
3. Liquid-Biopsy-Based Identification of EGFR T790M Mutation-Mediated Resistance to Afatinib Treatment in Patients with Advanced EGFR Mutation-Positive NSCLC, and Subsequent Response to Osimertinib.
Hochmair MJ; Buder A; Schwab S; Burghuber OC; Prosch H; Hilbe W; Cseh A; Fritz R; Filipits M
Target Oncol; 2019 Feb; 14(1):75-83. PubMed ID: 30539501
[TBL] [Abstract][Full Text] [Related]
4. Plasma screening for the T790M mutation of EGFR and phase 2 study of osimertinib efficacy in plasma T790M-positive non-small cell lung cancer: West Japan Oncology Group 8815L/LPS study.
Takahama T; Azuma K; Shimokawa M; Takeda M; Ishii H; Kato T; Saito H; Daga H; Tsuboguchi Y; Okamoto I; Otsubo K; Akamatsu H; Teraoka S; Takahashi T; Ono A; Ohira T; Yokoyama T; Sakai K; Yamamoto N; Nishio K; Nakagawa K
Cancer; 2020 Jan; 126(9):1940-1948. PubMed ID: 32022929
[TBL] [Abstract][Full Text] [Related]
5. Real-world data on efficacy and safety of osimertinib in non-small cell lung cancer patients with EGFR T790M mutation detected by first and repeat rebiopsy.
Wang Y; Zhang H; Zou Y; Ren X; Wang H; Bai R; Xu K; Xu Y; Zhang Z
Asia Pac J Clin Oncol; 2023 Dec; 19(6):715-722. PubMed ID: 36756895
[TBL] [Abstract][Full Text] [Related]
6. First and repeat rebiopsy for detecting EGFR T790M mutation in non-small-cell lung cancer: CS-Lung-003 prospective observational registry study.
Kudo K; Nishii K; Makimoto G; Ishikawa N; Tsubata Y; Kodani M; Fujimoto N; Yamasaki M; Kubota T; Takigawa N; Fujitaka K; Kanaji N; Shibayama T; Itano J; Ando C; Hotta K; Kiura K
J Cancer Res Clin Oncol; 2022 Aug; 148(8):1869-1877. PubMed ID: 35386002
[TBL] [Abstract][Full Text] [Related]
7. Frequency of EGFR T790M mutation and multimutational profiles of rebiopsy samples from non-small cell lung cancer developing acquired resistance to EGFR tyrosine kinase inhibitors in Japanese patients.
Ko R; Kenmotsu H; Serizawa M; Koh Y; Wakuda K; Ono A; Taira T; Naito T; Murakami H; Isaka M; Endo M; Nakajima T; Ohde Y; Yamamoto N; Takahashi K; Takahashi T
BMC Cancer; 2016 Nov; 16(1):864. PubMed ID: 27821131
[TBL] [Abstract][Full Text] [Related]
8. Combined plasma and tissue genotyping of EGFR T790M benefits NSCLC patients: a real-world clinical example.
Wei B; Zhao C; Li J; Zhao J; Ren P; Yang K; Yan C; Sun R; Ma J; Guo Y
Mol Oncol; 2019 May; 13(5):1226-1234. PubMed ID: 30927306
[TBL] [Abstract][Full Text] [Related]
9. Clinical Factors Predicting Detection of T790M Mutation in Rebiopsy for EGFR-Mutant Non-small-cell Lung Cancer.
Kawamura T; Kenmotsu H; Omori S; Nakashima K; Wakuda K; Ono A; Naito T; Murakami H; Omae K; Mori K; Tanigawara Y; Nakajima T; Ohde Y; Endo M; Takahashi T
Clin Lung Cancer; 2018 Mar; 19(2):e247-e252. PubMed ID: 28866043
[TBL] [Abstract][Full Text] [Related]
10. Plasma ctDNA monitoring during epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor treatment in patients with EGFR-mutant non-small cell lung cancer (JP-CLEAR trial).
Usui K; Yokoyama T; Naka G; Ishida H; Kishi K; Uemura K; Ohashi Y; Kunitoh H
Jpn J Clin Oncol; 2019 Jun; 49(6):554-558. PubMed ID: 30809659
[TBL] [Abstract][Full Text] [Related]
11. When compared to plasma-based detection, osimertinib-treated non-small cell lung cancer (NSCLC) with tissue rebiopsy-confirmed acquired T790M mutation is associated with better survival.
Kwok WC; Ho JCM; Lam DCL; Lui MMS; Ip MSM; Tam TCC
Asia Pac J Clin Oncol; 2021 Apr; 17(2):e35-e39. PubMed ID: 31802642
[TBL] [Abstract][Full Text] [Related]
12. A Phase II Trial of Osimertinib in the Second-Line Treatment of Non-small Cell Lung Cancer with the EGFR T790M Mutation, Detected from Circulating Tumor DNA: LiquidLung-O-Cohort 2.
Park CK; Cho HJ; Choi YD; Oh IJ; Kim YC
Cancer Res Treat; 2019 Apr; 51(2):777-787. PubMed ID: 30189719
[TBL] [Abstract][Full Text] [Related]
13. Rebiopsy for patients with non-small-cell lung cancer after epidermal growth factor receptor-tyrosine kinase inhibitor failure.
Kawamura T; Kenmotsu H; Taira T; Omori S; Nakashima K; Wakuda K; Ono A; Naito T; Murakami H; Mori K; Nakajima T; Ohde Y; Endo M; Takahashi T
Cancer Sci; 2016 Jul; 107(7):1001-5. PubMed ID: 27145431
[TBL] [Abstract][Full Text] [Related]
14. Real-world data on treatment outcomes in
Dal Maso A; Lorenzi M; Ferro A; Pilotto S; Cecere F; Follador A; Polo V; Del Conte A; Sartori G; Giavarra M; Scattolin D; Indraccolo S; Frega S; De Maglio G; Menis J; Bonanno L; Calabrese F; Guarneri V; Conte P; Pasello G
Future Oncol; 2021 Jul; 17(19):2513-2527. PubMed ID: 33988036
[TBL] [Abstract][Full Text] [Related]
15. Genomic landscape of acquired resistance to third-generation EGFR tyrosine kinase inhibitors in EGFR T790M-mutant non-small cell lung cancer.
Lee J; Kim HS; Lee B; Kim HK; Sun JM; Ahn JS; Ahn MJ; Park K; Lee SH
Cancer; 2020 Jun; 126(11):2704-2712. PubMed ID: 32154925
[TBL] [Abstract][Full Text] [Related]
16. Intercalated Treatment Following Rebiopsy Is Associated with a Shorter Progression-Free Survival of Osimertinib Treatment.
Tseng JS; Yang TY; Chen KC; Hsu KH; Huang YH; Su KY; Yu SL; Chang GC
Cancer Res Treat; 2018 Oct; 50(4):1164-1174. PubMed ID: 29228521
[TBL] [Abstract][Full Text] [Related]
17. EGFR T790M detection and osimertinib treatment response evaluation by liquid biopsy in lung adenocarcinoma patients with acquired resistance to first generation EGFR tyrosine kinase inhibitors.
Li C; Jia R; Liu H; Zhang B; Wang C
Diagn Pathol; 2018 Aug; 13(1):49. PubMed ID: 30103780
[TBL] [Abstract][Full Text] [Related]
18. Impact on prognosis of rebiopsy in advanced non-small cell lung cancer patients after epidermal growth factor receptor-tyrosine kinase inhibitor treatment: a systematic review.
Imakita T; Matsumoto H; Hirano K; Morisawa T; Sakurai A; Kataoka Y
BMC Cancer; 2019 Jan; 19(1):105. PubMed ID: 30683066
[TBL] [Abstract][Full Text] [Related]
19. Osimertinib benefit in EGFR-mutant NSCLC patients with T790M-mutation detected by circulating tumour DNA.
Remon J; Caramella C; Jovelet C; Lacroix L; Lawson A; Smalley S; Howarth K; Gale D; Green E; Plagnol V; Rosenfeld N; Planchard D; Bluthgen MV; Gazzah A; Pannet C; Nicotra C; Auclin E; Soria JC; Besse B
Ann Oncol; 2017 Apr; 28(4):784-790. PubMed ID: 28104619
[TBL] [Abstract][Full Text] [Related]
20. Osimertinib for patients with EGFR T790M mutation-positive non-small-cell lung cancer and a poor performance status.
Nakashima K; Kimura M; Akamatsu H; Daga H; Imai H; Taira T; Ko R; Hisamatsu Y; Nishino K; Sugimoto T; Miyashita Y; Takahashi T;
Jpn J Clin Oncol; 2019 Jul; 49(7):671-675. PubMed ID: 30920616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]